NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

NCT06781281 · clinicaltrials.gov ↗

RECRUITING

Status

709

Enrollment

OTHER_GOV

Sponsor class

Conditions

Breast Cancer Invasive

Interventions

DRUG: Serplulimab
DRUG: NabPE

Sponsor

Henan Cancer Hospital